Share on StockTwits

MKM Partners boosted their price target on shares of Merck & Co. (NYSE:MRK) from $64.00 to $70.00 in a research note issued on Friday, reports. The firm currently has a “buy” rating on the stock. MKM Partners’ price target suggests a potential upside of 25.34% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co. in a research note on Thursday, March 20th. They now have a $59.00 price target on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Merck & Co. to $57.00 in a research note on Wednesday, March 19th. Finally, analysts at Leerink Swann raised their price target on shares of Merck & Co. from $49.00 to $57.00 in a research note on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $57.64.

Shares of Merck & Co. (NYSE:MRK) traded up 0.61% during mid-day trading on Friday, hitting $56.19. The stock had a trading volume of 11,209,539 shares. Merck & Co. has a 52 week low of $44.60 and a 52 week high of $58.14. The stock has a 50-day moving average of $56.16 and a 200-day moving average of $51.15. The company has a market cap of $165.2 billion and a price-to-earnings ratio of 37.99. Merck & Co. also was the target of some unusual options trading on Thursday. Stock traders purchased 16,474 call options on the company. This is an increase of approximately 131% compared to the average volume of 7,127 call options.

Merck & Co. (NYSE:MRK) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.88 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.88. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $11.39 billion. During the same quarter in the previous year, the company posted $0.83 earnings per share. The company’s revenue for the quarter was down 3.6% on a year-over-year basis. Analysts expect that Merck & Co. will post $3.43 EPS for the current fiscal year.

In other Merck & Co. news, CEO Kenneth C. Frazier sold 10,047 shares of the company’s stock on the open market in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $57.24, for a total value of $575,090.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.